Erlotinib after Gefitinib failure in female never-smoker Asian patients with pulmonary adenocarcinoma

Lung Cancer

Volumn 65, Issue 2, 2009, Pages 204-207

  Sim, Sung Hoon ^a   Han, Sae Won ^a,b   Oh, Do Youn ^a,b   Lee, Se Hoon ^a,b   Kim, Dong Wan ^a,b   Im, Seock Ah ^a,b   Chung, Doo Hyun ^a,b   Kim, Tae You ^a,b   Lee, Jong Seok ^c   Kim, Young Whan ^a   Heo, Dae Seog ^a,b   Bang, Yung Jue ^a,b  

^a Seoul National University Hospital   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c Seoul National University Bundang Hospital   (South Korea)

Author keywords

Adenocarcinoma; Chemotherapy; Erlotinib; Gefitinib

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB;

ADULT; AGED; ARTICLE; CANCER CONTROL; CLINICAL ARTICLE; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG RESPONSE; DRUG TREATMENT FAILURE; FEMALE; HUMAN; LUNG ADENOCARCINOMA; PRIORITY JOURNAL; SOUTH KOREA;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; LUNG NEOPLASMS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; RISK FACTORS; SMOKING;

EID: 67449115698     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2008.11.006     Document Type: Article

References (15)

1. Janne P.A., Gurubhagavatula S., Yeap B.Y., Lucca J., Ostler P., Skarin A.T., et al. Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study. Lung Cancer 44 (2004) 221-230
2. Fukuoka M., Yano S., Giaccone G., Tamura T., Nakagawa K., Douillard J.Y., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 21 (2003) 2237-2246
3. Kris M.G., Natale R.B., Herbst R.S., Lynch Jr. T.J., Prager D., Belani C.P., et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290 (2003) 2149-2158
4. Han S.W., Kim T.Y., Lee K.H., Hwang P.G., Jeon Y.K., Oh D.Y., et al. Clinical predictors versus epidermal growth factor receptor mutation in gefitinib-treated non-small-cell lung cancer patients. Lung Cancer 54 (2006) 201-207
5. Hirsch F.R., Varella-Garcia M., Bunn Jr. P.A., Franklin W.A., Dziadziuszko R., Thatcher N., et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 24 (2006) 5034-5042
6. Cho B.C., Im C.K., Park M.S., Kim S.K., Chang J., Park J.P., et al. Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib. J Clin Oncol 25 (2007) 2528-2533
7. Wong A.S., Soong R., Seah S.B., Lim S.W., Chuah K.L., Nga M.E., et al. Evidence for disease control with erlotinib after gefitinib failure in typical gefitinib-sensitive Asian patients with non-small cell lung cancer. J Thorac Oncol 3 (2008) 400-404
8. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 (2000) 205-216
9. Han S.W., Kim T.Y., Hwang P.G., Jeong S., Kim J., Choi I.S., et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 23 (2005) 2493-2501
10. Sharma S.V., Bell D.W., Settleman J., and Haber D.A. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7 (2007) 169-181
11. Kim K.S., Jeong J.Y., Kim Y.C., Na K.J., Kim Y.H., Ahn S.J., et al. Predictors of the response to gefitinib in refractory non-small cell lung cancer. Clin Cancer Res 11 (2005) 2244-2251
12. Engelman J.A., Zejnullahu K., Mitsudomi T., Song Y., Hyland C., Park J.O., et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316 (2007) 1039-1043
13. Kosaka T., Yatabe Y., Endoh H., Yoshida K., Hida T., Tsuboi M., et al. Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin Cancer Res 12 (2006) 5764-5769
14. Gonzales A.J., Hook K.E., Althaus I.W., Ellis P.A., Trachet E., Delaney A.M., et al. Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor. Mol Cancer Ther 7 (2008) 1880-1889
15. Eskens F.A., Mom C.H., Planting A.S., Gietema J.A., Amelsberg A., Huisman H., et al. A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours. Br J Cancer 98 (2008) 80-85